Health Ever Bio-Tech
New Taipei City, Taiwan· Est.
Taiwanese biotech developing plant‑based oncology drugs, with a Phase II prostate cancer candidate.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwanese biotech developing plant‑based oncology drugs, with a Phase II prostate cancer candidate.
Oncology
Technology Platform
Plant‑derived compound discovery and development platform combining advanced phytochemical extraction, high‑throughput screening, and rigorous pre‑clinical validation to create safe, effective botanical drugs.
Opportunities
Successful Phase II results could unlock licensing deals and expansion into broader Asian markets, while the botanical platform may be leveraged to develop additional oncology or chronic disease candidates.
Risk Factors
Clinical trial failure, regulatory approval challenges, and competition from synthetic oncology drugs and other botanical developers could impede commercialization.
Competitive Landscape
Few companies focus on botanical oncology agents; Health Ever Bio-Tech differentiates through its plant‑derived pipeline and recent positive Phase II data, but must compete against larger pharma with greater resources.